Beacon Investment Advisory Services Inc. Sells 3,190 Shares of Boston Scientific Corporation $BSX

Key Points

• Beacon Investment Advisory Services Inc. reduced its stake in Boston Scientific Corporation by 30.2% during the second quarter, selling 3,190 shares and ending up with 7,356 shares valued at approximately $790,000.
• Multiple institutional investors increased their holdings in Boston Scientific, with Vanguard Group Inc. notably boosting its stake by 1.3%, owning over 134 million shares worth $13.58 billion.
• Boston Scientific's stock received several upgrades from analysts, with price targets raised by firms like Robert W. Baird and Raymond James, reflecting positive market sentiment with a consensus target price of $118.17.

Beacon Investment Advisory Services Inc. lowered its stake in shares of Boston Scientific Corporation (NYSE:BSX - Free Report) by 30.2% in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 7,356 shares of the medical equipment provider's stock after selling 3,190 shares during the quarter. Beacon Investment Advisory Services Inc.'s holdings in Boston Scientific were worth $790,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in BSX. Vanguard Group Inc. boosted its holdings in shares of Boston Scientific by 1.3% during the 1st quarter. Vanguard Group Inc. now owns 134,588,729 shares of the medical equipment provider's stock worth $13,577,311,000 after buying an additional 1,697,945 shares during the period. Invesco Ltd. lifted its position in Boston Scientific by 5.3% during the 1st quarter. Invesco Ltd. now owns 16,624,940 shares of the medical equipment provider's stock worth $1,677,124,000 after acquiring an additional 834,274 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in Boston Scientific by 10.8% during the 1st quarter. Goldman Sachs Group Inc. now owns 14,143,332 shares of the medical equipment provider's stock worth $1,426,779,000 after acquiring an additional 1,383,524 shares during the last quarter. Amundi boosted its holdings in Boston Scientific by 2.6% during the first quarter. Amundi now owns 12,308,715 shares of the medical equipment provider's stock valued at $1,212,408,000 after acquiring an additional 311,034 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its position in shares of Boston Scientific by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 11,299,942 shares of the medical equipment provider's stock valued at $1,139,938,000 after purchasing an additional 460,580 shares during the last quarter. Institutional investors and hedge funds own 89.07% of the company's stock.

Insiders Place Their Bets

In related news, EVP Joseph Michael Fitzgerald sold 50,000 shares of Boston Scientific stock in a transaction dated Tuesday, September 2nd. The stock was sold at an average price of $105.43, for a total value of $5,271,500.00. Following the completion of the transaction, the executive vice president directly owned 178,342 shares of the company's stock, valued at $18,802,597.06. The trade was a 21.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Yoshiaki Fujimori sold 2,901 shares of the company's stock in a transaction dated Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director owned 2,081 shares in the company, valued at approximately $222,646.19. This trade represents a 58.23% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock valued at $18,397,457. Company insiders own 0.50% of the company's stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on BSX. Robert W. Baird boosted their price objective on Boston Scientific from $117.00 to $123.00 and gave the stock an "outperform" rating in a research report on Thursday, July 24th. Raymond James Financial upped their price target on Boston Scientific from $121.00 to $124.00 and gave the stock a "strong-buy" rating in a report on Thursday, July 24th. Leerink Partnrs raised Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. BTIG Research reaffirmed a "buy" rating and set a $127.00 target price on shares of Boston Scientific in a research report on Tuesday. Finally, Jefferies Financial Group reissued a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Three research analysts have rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $118.17.

Boston Scientific Price Performance

Shares of Boston Scientific stock opened at $98.03 on Friday. The firm has a market cap of $145.26 billion, a P/E ratio of 58.35, a price-to-earnings-growth ratio of 2.36 and a beta of 0.65. The firm's 50-day simple moving average is $103.90 and its 200-day simple moving average is $102.06. Boston Scientific Corporation has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37.

Boston Scientific (NYSE:BSX - Get Free Report) last announced its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, beating the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion for the quarter, compared to analyst estimates of $4.89 billion. During the same quarter in the previous year, the firm earned $0.62 EPS. Boston Scientific's quarterly revenue was up 22.8% on a year-over-year basis. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. As a group, research analysts expect that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.